Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome

European Heart Journal

Volumn 23, Issue 12, 2002, Pages 975-983

  Noda, T ^a   Takaki, H ^a   Kurita, T ^a   Suyama, K ^a   Nagaya, N ^a   Taguchi, A ^a   Aihara, N ^a   Kamakura, S ^a   Sunagawa, K ^a   Nakamura, K ^b   Ohe, T ^b   Horie, M ^c   Napolitano, C ^d   Towbin, J A ^e   Priori, S G ^d   Shimizu, Wataru ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d IRCCS   (Italy)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Action potentials; Catecholamines; Genetics; Long QT syndrome; Nervous system; Sympathetic

Indexed keywords

ADRENALIN; POTASSIUM CHANNEL;

ADOLESCENT; ADRENERGIC STIMULATION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; GENOTYPE; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; LONG QT SYNDROME; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SODIUM CALCIUM EXCHANGE;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; AGED; CHILD; CHILD WELFARE; CHILD, PRESCHOOL; ELECTROCARDIOGRAPHY; EPINEPHRINE; FEMALE; GENE EXPRESSION REGULATION; HEART CONDUCTION SYSTEM; HUMANS; INFUSIONS, INTRAVENOUS; LONG QT SYNDROME; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 0036623671     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.3079     Document Type: Article

References (22)

1. Schwartz PJ, Periti M, Malliani A. The long QT syndrome. Am Heart J 1975; 89: 378-90.
2. Moss AJ, Schwartz PJ, Crampton RS, Locati E, Carleen E. The long QT syndrome: A prospective international study. Circulation 1985; 71: 17-21.
3. Moss AJ, Schwartz PJ, Crampton RS et al. The long QT syndrome: Prospective longitudinal study of 328 families. Circulation 1991; 84: 1136-44.
4. Roden DM, Lazzara R, Rosen MR, Schwartz PJ, Towbin JA, Vincent GM. Multiple mechanisms in the long-QT syndrome: Current knowledge, gaps, and future directions. Circulation 1996; 94: 1996-2012.
5. Priori SG, Barhanin J, Hauer RNW et al. Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management parts I and II. Circulation 1999; 99: 518-28.
6. Abbott GW, Sesti F, Splawski I et al. MiRPI forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999; 97: 175-87.
7. Schwartz PJ, Priori SG, Spazzolini C et al. Genotype-phenotype correlation in the long-QT syndrome: Gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103: 89-95.
8. Moss AJ, Robinson JL, Gessman L et al. Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol 1999; 84: 876-9.
9. Wilde AAM, Jongbloed RJE, Doevendans PA et al. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQT2) patients from KVLQT1-patients (LQT1). J Am Coll Cardiol 1999; 33: 327-32.
10. Zareba W, Moss AJ, Schwartz PJ et al. Influence of the genotype on the clinical course of the long-QT syndrome. N Engl J Med 1998; 339: 960-5.
11. Shimizu W, Antzelevitch C. Cellular basis for the electrocardiographic features of the LQT1 form of the long QT syndrome: Effects of β-adrenergic agonists, antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation 1998; 98: 2314-22.
12. Shimizu W, Antzelevitch C. Differential response to beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol 2000; 35: 778-86.
13. Moss AJ, Zareba W, Benhorin J et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995; 92: 2929-34.
14. Davidenko JM, Cohen L, Goodrow R, Antzelevitch C. Quinidine-induced action potential prolongation, early after-depolarizations, and triggered activity in canine Purkinje fibers: Effects of stimulation rate, potassium, and magnesium. Circulation 1989; 79: 674-86.
15. + channel blockade, β-adrenergic simulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome. Circ Res 1996; 78: 1009-15.
16. Shimizu W, Ohe T, Kurita T et al. Early afterdepolarizations induced by isoproterenol in patients with congenital long QT syndrome. Circulation 1991; 84: 1915-23.
17. Shimizu W, Kurita T, Matsuo K et al. Improvement of repolarization abnormalities by a K+ channel opener in the LQT1 form of congenital long QT syndrome. Circulation 1998; 97: 1581-8.
18. Antzelevitch C, Yan GX, Shimizu W, Burashnikov A. Electrical heterogeneity, the ECG, and cardiac arrhythmias. In Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside, 3rd Edn. Philadelphia: W.B. Saunders Co., 1999: 222-38.
19. Shimizu W, Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation 1997; 96: 2038-47.
20. Viswanathan PC, Rudy Y. Cellular arrhythmogenic effects of the congenital and acquired long QT syndrome in the heterogeneous myocardium. Circulation 2000; 101: 1192-8.
21. + channel blockade and to increases in heart rate: Implications for gene-specific therapy. Circulation 1995; 92: 3381-6.
22. Stramba-Badiale M, Priori SG, Napolitano C et al. Gene-specific differences in the circadian variation of ventricular repolarization in the long QT syndrome: A key to sudden death during sleep? Ital Heart J 2000; 1: 323-8.